AEMDHIGH SIGNALRISK10-K

AEMD received a going concern qualification from auditors for fiscal 2025, indicating substantial doubt about the company's ability to continue operations.

The addition of going concern language represents a material deterioration in the company's financial stability and survival prospects. While operating losses improved, the auditor qualification suggests liquidity concerns that could lead to bankruptcy, dilutive financing, or business closure if not addressed.

Comparing 2025-06-26 vs 2024-06-27View on EDGAR →
FINANCIAL ANALYSIS

AEMD showed mixed operational improvements with operating losses narrowing 26% to $9.3M and operating cash flow losses decreasing 25% to $7.6M, while R&D expenses declined 12% to $2.2M. However, the balance sheet contracted with total assets falling 11% to $7.4M and stockholders' equity declining to $5.1M, reflecting a company burning through its financial resources. The dramatic 97% reduction in interest expense suggests potential debt restructuring or paydown, but the overall picture points to a cash-strapped company facing existential financial challenges despite modest operational improvements.

FINANCIAL STATEMENT CHANGES
Interest Expense
P&L
-97.1%
$350K$10K

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

Operating Income
P&L
+26.1%
-$12.6M-$9.3M

Operating income improving — cost discipline or growing revenue base absorbing fixed costs.

Operating Cash Flow
Cash Flow
+24.5%
-$10.1M-$7.6M

Operating cash flow grew 24.5% — strong conversion of earnings to cash, healthy business fundamentals.

R&D Expense
P&L
-12.2%
$2.5M$2.2M

R&D spending cut 12.2% — could signal cost discipline or concerning reduction in innovation investment.

Stockholders Equity
Balance Sheet
-11.1%
$5.8M$5.1M

Equity decreased 11.1% — buybacks or losses reducing book value, monitor solvency ratios.

Total Assets
Balance Sheet
-10.8%
$8.2M$7.4M

Total assets contracted 10.8% — asset sales, write-downs, or balance sheet optimization underway.

LANGUAGE CHANGES
NEW — 2025-06-26
PRIOR — 2024-06-27
ADDED
They are neither statements of historical fact nor guarantees of assurance of future performance.
As a result, our financial statements for the fiscal year ended March 31, 2025 carry a going concern qualification by our independent auditors.
Overview and Corporate History Overview We are a medical therapeutic company focused on developing the Hemopurifier (HP), a clinical-stage immunotherapeutic device intended for applications in cancer, life-threatening viral infections, and organ transplantation and other areas of significant unmet needs.
In human studies (164 sessions with 38 patients), the Hemopurifier was used safely and demonstrated the potential to remove enveloped viruses.
In pre-clinical studies, the Hemopurifier has exhibited the capacity to remove harmful extracellular vesicles (EVs) and enveloped viruses from biological fluids, utilizing its proprietary lectin-based mechanism.
+7 more — sign up free →
REMOVED
Such proxy statement will be filed with the SEC not later than 120 days following the end of the registrant s fiscal year ended March 31, 2024.
They are neither statement of historical fact nor guarantees of assurance of future performance.
Overview and Corporate History Overview We are a medical therapeutic company focused on developing the Hemopurifier, a clinical-stage immunotherapeutic device designed to combat cancer and life-threatening viral infections and for use in organ transplantation.
In human studies, 164 sessions with 38 patients, the Hemopurifier was safely utilized and demonstrated the potential to remove life-threatening viruses.
In pre-clinical studies, the Hemopurifier has demonstrated the potential to remove harmful exosomes and exosomal particles from biological fluids, utilizing its proprietary lectin-based technology.
+7 more — sign up free →
MORE RISK SIGNALS
CAPSHIGHCAPS underwent a major business expansion through acquisitions while experiencin...
2026-04-16
KALAHIGHKALA has undergone a dramatic business transformation with massive share dilutio...
2026-04-15
RAINHIGHRain Enhancement Technologies underwent a financial restatement revealing signif...
2026-04-15
POLAHIGHPOLA experienced severe financial deterioration with gross profit turning negati...
2026-04-15
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →